



Dynavax Technologies Corporation  
Investor Relations Department  
2929 Seventh Street  
Berkeley, CA 94710  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: DVAX

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 17.40                      |
| Trade Time:   | 4:00 PM ET<br>Feb 21, 2018 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | N/A - N/A                  |
| 52-Week Range | 3.90 - 24.45               |
| Volume        | N/A                        |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 21, 2018*

[Dynavax's HEPLISAV-B™ \[Hepatitis B Vaccine \(Recombinant\), Adjuvanted\] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults](#)

*Feb 20, 2018*

[Dynavax Secures \\$175 Million in Non-Dilutive Debt Financing](#)

*Feb 14, 2018*

[Dynavax to Present at the RBC Capital Markets Global Healthcare Conference](#)

*Feb 2, 2018*

[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

*Jan 12, 2018*

[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 13, 2017*

[Annual Report \(10-K\)](#)

*Jul 10, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 3, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 7, 2017*

[Quarterly Report \(10-Q\)](#)

*May 8, 2017*

[Quarterly Report \(10-Q\)](#)